By Tony Winterburn • Published: 03 Feb 2021 • 10:37
Scientists found PharmaMar’s myeloma drug plitidepsin, derived from sea squirts, might be a more potent anti-COVID-19 drug than Gilead's remdesivir. (Quantitative Biosciences Institute)
Hopes For New Covid-19 Treatment After Promising Antiviral Drug Development.
The discovery of a new drug has raised hopes of a breakthrough in treatment for the most severe cases of Covid-19 after trials of an existing blood cancer drug found it was up to 100 times more effective against the virus than redeliver, a similar class of ‘antiviral’ drug that is currently being used by the NHS.
Researchers cautioned that most of the experiments were conducted on mice and human cells in the lab – rather than in people going about their everyday lives – meaning much more research is needed to confirm the drug’s promise, although they did said it was an exciting breakthrough that could save many lives.
The way that antiviral drugs work is by stopping the infection process by disabling dangerous parts of the viruses proteins. Researchers tested Aplidin, also known as Plitdepsin, a treatment approved for the multiple myeloma blood cancer in Australia that was developed by Spanish company Pharma Mar.
In the laboratory process, Aplidin is extracted from Aplidium Albicans, a sea squirt found off the coast of Spain.
In trials, the drug was found to be between 10 and 100 times more effective at tackling Covid, including the new UK variant, than Remdesivir – and at least ten times more potent at stopping people with the virus from passing it on, according to research by University College London, published on the ‘pre-print’ website bioRxiv ahead of peer-reviews.
Thank you for taking the time to read this news article “Hopes For New Covid-19 Treatment After Promising Antiviral Drug Development”. For more UK daily news, Spanish daily news and Global news stories, visit the Euro Weekly News home page.
Share this story
Subscribe to our Euro Weekly News alerts to get the latest stories into your inbox!
By signing up, you will create a Euro Weekly News account if you don't already have one. Review our Privacy Policy for more information about our privacy practices.
Share your story with us by emailing newsdesk@euroweeklynews.com, by calling +34 951 38 61 61 or by messaging our Facebook page www.facebook.com/EuroWeeklyNews
By signing up, you will create a Euro Weekly News account if you don’t already have one. Review our Privacy Policy for more information about our privacy practices.
Download our media pack in either English or Spanish.